Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

uarter ended September 30, 2009 are scheduled for Monday, November 16, 2009, after the market closes. Encorium will hold a conference call at 11:00 a.m. EST Tuesday, November 17, 2009, to discuss its financial results and corporate developments. Additional details will be forthcoming.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... IRVINE, CA (PRWEB) , ... August 28, 2015 ... ... leader in Personalized Medicine, presented two studies at the International Spine Intervention ... on July 28th, 2015 through to August 1st, 2015. With a focus on ...
(Date:8/28/2015)... ... 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company ... Images such as the Fonz in a lab coat and Large Marge have been ... spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer is ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... systems, will exhibit CT Laser Mammography (CTLM(R)),technology ... Cancer,Conference, March 1-5, in Las Vegas, Nevada. ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ), "Attending ...
... SAN DIEGO, Feb. 27 NuVasive, Inc. (Nasdaq:,NUVA), a ... surgical treatments for the spine, announced today,that Kevin O,Boyle, ... present at the Canaccord Adams, Small-Cap Orthopedics,Conference at The ... on Tuesday, March 4, 2008 at 8:10 a.m. PT., ...
... Ocera Therapeutics, a,biopharmaceutical company focused on the ... a broad range of,gastrointestinal and liver diseases, announced ... company as Chief Medical Officer. Prior to joining,Ocera, ... Officer and Vice,President of Clinical Affairs at Napo ...
Cached Biology Technology:CT Laser Mammography Technology to be Featured at Interdisciplinary Breast Cancer Conference 2NuVasive to Present at Canaccord Adams' Small-Cap Orthopedics Conference 2NuVasive to Present at Canaccord Adams' Small-Cap Orthopedics Conference 3M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer 2
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... major research findings at the 11th International Coral Reef Symposium ... African Dust Poses Threat to Coral Reefs and Human ... Caribbean and the Americas may be a threat to marine ... study by researchers with the U.S. Geological Survey, Oregon State ...
... Researchers from Harvard Medical School and Brandeis University have ... what types of genes are necessary for brain development. ... are published July 4th in the open-access journal PLoS ... sequencing of entire genomes and the discovery of RNA-interference ...
... the biggest challenges facing humanity is to halt the destruction ... task that must be urgently addressed and in which we ... is our duty to do all we can for the ... researchers Harold Mooney and Peter Raven, regarded as the architects ...
Cached Biology News:The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 2The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 3The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 4The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 5The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 6The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 7The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 8The good, the bad and the smelly: USGS at the 2008 Coral Reef Symposium 9Researchers reveal types of genes necessary for brain development 2BBVA Foundation Awards for Biodiversity Conservation 2BBVA Foundation Awards for Biodiversity Conservation 3BBVA Foundation Awards for Biodiversity Conservation 4
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Alkaline Phosphatase Stabilizer Solution, 1 L...
Biology Products: